Literature DB >> 15516472

Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome.

R Menéndez1, A Torres, R Zalacaín, J Aspa, J J Martín Villasclaras, L Borderías, J M Benítez Moya, J Ruiz-Manzano, F Rodríguez de Castro, J Blanquer, D Pérez, C Puzo, F Sánchez Gascón, J Gallardo, C Alvarez, L Molinos.   

Abstract

BACKGROUND: An inadequate response to initial empirical treatment of community acquired pneumonia (CAP) represents a challenge for clinicians and requires early identification and intervention. A study was undertaken to quantify the incidence of failure of empirical treatment in CAP, to identify risk factors for treatment failure, and to determine the implications of treatment failure on the outcome.
METHODS: A prospective multicentre cohort study was performed in 1424 hospitalised patients from 15 hospitals. Early treatment failure (<72 hours), late treatment failure, and in-hospital mortality were recorded.
RESULTS: Treatment failure occurred in 215 patients (15.1%): 134 early failure (62.3%) and 81 late failure (37.7%). The causes were infectious in 86 patients (40%), non-infectious in 34 (15.8%), and undetermined in 95. The independent risk factors associated with treatment failure in a stepwise logistic regression analysis were liver disease, pneumonia risk class, leucopenia, multilobar CAP, pleural effusion, and radiological signs of cavitation. Independent factors associated with a lower risk of treatment failure were influenza vaccination, initial treatment with fluoroquinolones, and chronic obstructive pulmonary disease (COPD). Mortality was significantly higher in patients with treatment failure (25% v 2%). Failure of empirical treatment increased the mortality of CAP 11-fold after adjustment for risk class.
CONCLUSIONS: Although these findings need to be confirmed by randomised studies, they suggest possible interventions to decrease mortality due to CAP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15516472      PMCID: PMC1746855          DOI: 10.1136/thx.2003.017756

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  30 in total

1.  Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Authors:  B G Feagan; T J Marrie; C Y Lau; S L Wheeler; C J Wong; M K Vandervoort
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Trends in infectious disease mortality in the United States during the 20th century.

Authors:  G L Armstrong; L A Conn; R W Pinner
Journal:  JAMA       Date:  1999-01-06       Impact factor: 56.272

Review 3.  [Initial empirical antibiotic treatment of community-acquired pneumonia].

Authors:  J Frías; M Gomis; J Prieto; J Mensa; E Bouza; J A García-Rodríguez; A Torres; J Dorca; R Zalacaín; J García de Lomas
Journal:  Rev Esp Quimioter       Date:  1998-09       Impact factor: 1.553

4.  Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals.

Authors:  V Dudas; A Hopefl; R Jacobs; B J Guglielmo
Journal:  Ann Pharmacother       Date:  2000-04       Impact factor: 3.154

5.  Cytokine expression in severe pneumonia: a bronchoalveolar lavage study.

Authors:  C Montón; A Torres; M El-Ebiary; X Filella; A Xaubet; J P de la Bellacasa
Journal:  Crit Care Med       Date:  1999-09       Impact factor: 7.598

6.  Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.

Authors:  F Arancibia; S Ewig; J A Martinez; M Ruiz; T Bauer; M A Marcos; J Mensa; A Torres
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

7.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.

Authors:  P P Gleason; T P Meehan; J M Fine; D H Galusha; M J Fine
Journal:  Arch Intern Med       Date:  1999-11-22

8.  The cost of treating community-acquired pneumonia.

Authors:  M S Niederman; J S McCombs; A N Unger; A Kumar; R Popovian
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

9.  Temporal trends in outcomes of older patients with pneumonia.

Authors:  M L Metersky; J P Tate; M J Fine; M K Petrillo; T P Meehan
Journal:  Arch Intern Med       Date:  2000 Dec 11-25

Review 10.  Nonresolving or slowly resolving pneumonia.

Authors:  T Kuru; J P Lynch
Journal:  Clin Chest Med       Date:  1999-09       Impact factor: 2.878

View more
  67 in total

Review 1.  [Sense and nonsense in antibiotic therapy for respiratory tract infections].

Authors:  W Domej; E Flögel; G P Tilz; U Demel
Journal:  Internist (Berl)       Date:  2005-07       Impact factor: 0.743

2.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

3.  Bacteraemic community-acquired pneumonia due to Gram-negative bacteria: incidence, clinical presentation and factors associated with severity during hospital stay.

Authors:  L A Ruiz; A Gómez; C Jaca; L Martínez; B Gómez; R Zalacain
Journal:  Infection       Date:  2010-09-29       Impact factor: 3.553

4.  Bacterial community-acquired pneumonia: risk factors for mortality and supportive therapies.

Authors:  H Lode
Journal:  Intensive Care Med       Date:  2008-12-10       Impact factor: 17.440

5.  A 44-year-old man with a parapneumonic effusion.

Authors:  Jeffrey Craig; Wayne L Gold; Jerome A Leis
Journal:  CMAJ       Date:  2013-01-14       Impact factor: 8.262

Review 6.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

7.  Risk Stratification in Patients with Complicated Parapneumonic Effusions and Empyema Using the RAPID Score.

Authors:  Sunkaru Touray; Rahul N Sood; Daniel Lindstrom; Jonathan Holdorf; Sumera Ahmad; Daniel B Knox; Andres F Sosa
Journal:  Lung       Date:  2018-08-11       Impact factor: 2.584

Review 8.  Adjunct corticosteroid treatment in patients with pneumonia: A precision medicine approach.

Authors:  Srdjan Gavrilovic; Ana Andrijevic; Aida Mujakovic; Yewande Odeyemi; Belma Paralija; Ognjen Gajic
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

9.  Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials.

Authors:  Konstantinos Z Vardakas; Ilias I Siempos; Alexandros Grammatikos; Zoe Athanassa; Ioanna P Korbila; Matthew E Falagas
Journal:  CMAJ       Date:  2008-12-02       Impact factor: 8.262

10.  Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia.

Authors:  Oriol Sibila; Eric M Mortensen; Antonio Anzueto; Elena Laserna; Marcos I Restrepo
Journal:  Eur Respir J       Date:  2013-04-18       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.